Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

NCT00434954 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

494

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: exenatide twice daily (BID)
DRUG: premixed insulin aspart twice daily (BID)

Sponsor

AstraZeneca

Collaborators

[object Object]